![]() | |||||
disease | |||||
新闻 | |||||
| |||||
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved ... - PR Newswire Among patients who were in clinical remission at one year in VIVID-1, 92.9% maintained clinical remission at two years as measured by Crohn's Disease ...
| |||||
FDA Approves Supernus Pharmaceuticals' Onapgo for Managing Motor Fluctuations in ... ... disease. Advertisement. Closeup of the hands of a young woman holding ... disease (PD). According to the company, Onapgo will offer continuous ...
| |||||
查看更多结果 | 修改此快讯 |
您收到此电子邮件是因为您订阅了Google快讯。 |
![]() |
发送反馈 |
No comments:
Post a Comment